AMPLIFIED
44 evidence topics · 11 sources
Objective
Aim stated in the design abstract
Populations outside the pivotal trial stated by the company
Planned study announced by the company
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-02-04” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-07-20” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2026-07-20” (opens the source at this quote in a new tab)
“First Posted 2025-01-27” (opens the source at this quote in a new tab)
“Last Update Posted 2026-08-20” (opens the source at this quote in a new tab)
“Completed” (opens the source at this quote in a new tab)
“No Results Posted” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by state in the ClinicalTrials.gov record
Completion of enrollment reported in the first quarter 2026 results
Completion of enrollment and dosing reported in the second quarter 2026 results
Study design
Official title in the ClinicalTrials.gov record
Design details in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
Single-arm, open-label design with two reported cohorts
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
Age, sex, and healthy volunteers in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Ages eligible for study | “18 Years to 67 Years” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “No” |
Proteinuria thresholds by cohort in the design abstract
Proteinuria thresholds by cohort stated with the results
Treatment
Arm and intervention in the ClinicalTrials.gov record
Dose and background therapy stated with the results
Study outcomes
Rationale for using percent change in UACR as the primary endpoint
Registered primary and secondary outcome measures in the ClinicalTrials.gov record
Primary and other endpoints stated with the results
Albuminuria change as a surrogate endpoint across 48 randomized trials
“Here, in an individual participant data analysis of 48 randomized controlled trials (studies) involving 85,681 participants, we assessed the association between treatment effects on 6-month urinary albumin:creatinine ratio (UACR) change and the established clinical endpoint of kidney failure or doubling of serum creatinine concentrations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clear evidence that this association varied by CKD etiology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change and kidney outcomes in APOL1-mediated kidney disease
“Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Conditions under which albuminuria reduction is considered a reasonably likely surrogate
“It was considered that changes in albuminuria may be informative when baseline albuminuria is large and has a dominant role in disease progression and the therapeutic under investigation has a mechanistic relationship to reduce albuminuria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison with the phase 2a result stated by the company
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Participants dosed and analyzed by cohort stated with the results
| Cohort | Enrolled and dosed | Efficacy analysis | On treatment with a week 13 assessment |
|---|---|---|---|
| Cohort 1: AMKD with modest proteinuria | “N=23” | “N=22” | “18 and 14 people in cohort 1 and 2, respectively” |
| Cohort 2: AMKD with type 2 diabetes | “N=18” | “N=17” | “18 and 14 people in cohort 1 and 2, respectively” |
Description of analysis sets
Efficacy analysis set and week 13 analysis population
Geometric mean percent change by cohort and post hoc confidence intervals
Results
Participant disposition
Participants enrolled, dosed, and excluded from the efficacy analyses
Baseline characteristics
Baseline UACR and UPCR by cohort
| Measure | Cohort 1: AMKD with modest proteinuria | Cohort 2: AMKD with type 2 diabetes |
|---|---|---|
| Mean baseline UACR g/g (standard deviation) | “0.28 (0.09)” | “0.67 (0.87)” |
| Mean baseline UPCR g/g (standard deviation) | “0.46 (0.20)” | “1.12 (1.51)” |
FSGS diagnosis and background kidney therapy
FSGS diagnosis in both cohorts stated on the earnings call
Efficacy results
Percent change in UACR and UPCR at week 13 by cohort
| Endpoint | Cohort 1: AMKD with modest proteinuria | Cohort 2: AMKD with type 2 diabetes |
|---|---|---|
| Primary: geometric mean percent change in UACR at week 13 (95% confidence interval) | “-42.7%”; “(-58.3%, -21.1%)” | “-17.3%”; “(-36.3%, 7.2%)” |
| Other: geometric mean percent change in UPCR at week 13 (95% confidence interval) | “-44.7%”; “(-60.9%, -21.9%)” | “-25.4%”; “(-45.1%, 1.4%)” |
Cohort 1: AMKD with modest proteinuria
Cohort 2: AMKD with type 2 diabetes
Results restated in the third quarter 2026 results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Serious adverse events, severity, headache, and transaminase elevations
Study limitations
Summary: study limitations
AMPLIFIED was a single-arm, open-label study without a placebo or active comparator, so each cohort's result is a change from baseline over 13 weeks of inaxaplin 45 mg once daily added to “optimized standard of care”. Of 41 participants enrolled and dosed (23 in cohort 1 and 18 in cohort 2), 39 were in the efficacy analyses, and the week 13 analyses included 18 and 14 participants; the registry lists an actual enrollment of 42. The 95% confidence intervals “were generated post-hoc”, and in cohort 2 they include no change for both UACR (-36.3% to 7.2%) and UPCR (-45.1% to 1.4%). The design abstract planned 45 participants, including a third cohort of 15 participants with sickle cell disease, HIV, or lupus nephritis, which the results announcement does not report. The registry lists UACR as the only efficacy outcome measure, and UPCR is reported as an “other” endpoint. All 35 registered sites are in the United States, eligibility was limited to ages 18 to 67 years with eGFR of at least 25 mL/min/1.73 m2, and the only baseline characteristics reported are mean UACR and UPCR by cohort. The study measured no kidney function outcome. The AMKD-specific analysis supporting UACR change as a surrogate endpoint used 12-month changes in 128 participants without diabetes and with UACR of at least 420 mg/g, a range that excludes the cohort 1 eligibility range (UACR at least 100 to below 420 mg/g) and the cohort 2 population. As of 2026-11-15 the results are available only from company communications: the registry shows “No Results Posted”, and no peer-reviewed publication or congress presentation of the results was identified.